You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    AbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. PLATFORM FOR NEUROCOGNITIVE EVALUATION AND MONITORING

    SBC: ENFORMIA INC.            Topic: NCI

    Current standardized neuropsychological tests are based on decades old paper and pencil methods They lack reliability sensitivity specificity repeatability and require trained neuropsychologists to administer them Their administration in clinical and research settings result in high cost complexity and inconsistent results There is a need and a commercial opportunity for an extensible co ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. An RNA targeted platform for anti flavivirus drug discovery

    SBC: Ribometrix LLC            Topic: NIAID

    SUMMARY Emerging and re emerging mosquito borne flaviviruses cause widespread mortality morbidity and economic burden Options for prevention and treatment of mosquito borne flaviviruses are limited Flavivirus vaccines face unique development challenges no antiviral therapies are available and the mosquito vectors have proven difficult to eradicate Despite vaccines against Yellow Fever and J ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development of user-friendly fluorescence based assays for marine toxins

    SBC: SEATOX RESEARCH INC            Topic: 113

    ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Enhancing cytarabine efficacy in leukemia through CDK inhibition

    SBC: SENEX BIOTECHNOLOGY, INC.            Topic: 102

    Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS

    SBC: DEKK-TEC INC            Topic: NCI

    The goal of this Phase I clinical trial will be to document safety and potential usefulness ofdemethylcholesteryloxycarbonylpenclomedineDM CHOC PENin combination with de escalating doses of whole brain radiation therapyWBRTas binary therapy in subjects with advanced cancer involving the CNSa Phase I clinical trialDM CHOC PEN is a polychlorinated pyridyl cholesteryloxycarbonatewhich has completed P ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Peptide based tool for the rapid isolation of quiescent monocytes from peripheral blood

    SBC: AFFINERGY, LLC            Topic: 102

    SUMMARY ABSTRACT Dendritic cell DC therapy represents a new and promising immunotherapeutic approach for treatment of advanced stage cancers with DC vaccines already approved for use in advanced prostate cancer and more than DC based vaccines in the clinical development pipeline for other cancers In particular the US market for cancer vaccines including DC based vaccines is set to expan ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. IND Enabling Studies of ZB an Orally Bioavailable SERD

    SBC: Zenopharm, LLC            Topic: 102

    IND enabling Studies of ZB an Orally Bioavailable SERD Project Summary Most patients with advanced metastatic breast cancer eventually develop resistance to tamoxifen or aromatase inhibitor AI treatment where the recurrent and or progressive disease retains the expression of ER The standard treatment of breast cancer progressing after tamoxifen or AI therapy is fulvestrant which is the onl ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel injectable resiquimod formulation for treatment of metastatic cancers

    SBC: Curebiotech, Inc.            Topic: NCI

    PROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens

    SBC: Theragnostic Technologies Inc.            Topic: NIAID

    Abstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government